04 Jun 2012, BioSpectrum Bureau , BioSpectrum
Singapore: Australian drug development company Agenix has appointed international biomedical business development expert Dr Paul Resnick as business advisor for initially focusing on the company's revolutionary blood clot diagnostic ThromboView.
Dr Resnick is the former vice president of Business Development at privately held US-based biotechnology business Intellikine. He played a key role at Intellikine in securing a $489 million program licensing deal and the subsequent sale of the business in December 2011 to Japan's Takeda Pharmaceutical for $310 million.
Before joining Intellikine, Dr Resnick was senior director of Worldwide Business Development at Pfizer. He previously held roles at Rinat Neuroscience, InterMune, Roche Pharmaceuticals and practiced medicine. At Rinat Neuroscience, he played a key role in its acquisition by Pfizer.
Mr Nicholas Weston, chairman and chief executive officer, Agenix, said, "Paul adds significant depth and experience to our team and will provide strategic guidance and negotiation support as we progress our promising commercial and clinical programs."
Dr Resnick said, "I see significant unrecognized potential and value in Agenix and the exciting assets it has developed. There is a compelling proposition in ThromboView's strong clinical safety and efficacy profile and its potential value in a range of clinical applications."